Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of NSAIDS
View Patent ↗Novel process and products thereby emplace NSAIDS within nanodelivery vehicles for various indications in mammals, including humans.
1. A method of administering NSAIDS to a mammal, comprising;
(a) providing a composition formulation comprising nanoparticles comprising NSAIDS, essential phospholipids, fatty acids and solvents, wherein NSAIDs comprise 25-75% of the carrier composition formulation, wherein the essential phospholipids comprise more than 75% of (3-sn-phosphatidyl) choline; and wherein the fatty acids are selected from the group consisting of medium chain triglycerides which are liquid at room temperature, safflower seed oil and sunflower oil, and solvents; wherein the nanoparticles have a particle size distribution from 50 to 150 nm; wherein the nanoparticles do not comprise a polymer, and wherein the NSAIDs are encapsulated in the nanoparticle, and
(b) administering the composition formulation to a mammal via the sublingual or buccal mucosa.
2. A method of administering NSAIDS to a mammal, comprising;
(a) providing a composition formulation comprising nanoparticles comprising NSAIDS, essential phospholipids, fatty acids and solvents, wherein NSAIDs comprise 5-25% of the carrier composition formulation, wherein the essential phospholipids comprise more than 75% of (3-sn-phosphatidyl) choline; and wherein the fatty acids are selected from the group consisting of medium chain triglycerides which are liquid at room temperature, safflower seed oil and sunflower oil, and solvents; wherein the nanoparticles have a particle size distribution from 50 to 150 nm; wherein the nanoparticles do not comprise a polymer, and wherein the NSAIDs are encapsulated in the nanoparticle,
(b) administering the composition formulation to a mammal across ocular barriers into ocular tissues, and
(c) administering the nanoparticle structure to a mammal directing nose-to-brain drug delivery into CNS via the intranasal route of administration wherein the Blood Brain Barrier is bypassed.